Top entities: Lundbeck, South Korea, South Korea — Ministry of Food and Drug Safety, Johan Luthman, United States — Food and Drug Administration.

What category does this event fall under?

Business — classified as marketing authorization.

What is the sentiment of coverage?

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 26, 2026. Coverage continues to evolve.

Business marketing authorization

H. Lundbeck receives South Korea migraine drug approval

Q: When did this event occur?

First reported May 26, 2026; last updated May 26, 2026.

Q: What is the market impact?

Direct. The marketing authorization for eptinezumab in South Korea is expected to positively impact Lundbeck's stock price due to expanded market access and potential revenue growth.

Analysis based on 7 articles · First reported May 26, 2026 · Last updated May 26, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The marketing authorization for eptinezumab in South Korea is expected to positively impact Lundbeck's stock price due to expanded market access and potential revenue growth. It also provides a new treatment option for migraine patients in South Korea, potentially affecting the healthcare market in the region.

Pharmaceuticals Healthcare

Event Summary

Lundbeck announced that the South Korea — Ministry of Food and Drug Safety of South Korea has granted marketing authorization for eptinezumab (Vyepti) for the preventive treatment of migraine in adults. This approval is a significant milestone for Lundbeck, expanding its global reach for the intravenous migraine treatment, which has already been approved by the United States — Food and Drug Administration and the International — European Commission and launched in over 30 markets worldwide. The decision is supported by results from several Phase 3 trials, including the SUNRISE trial conducted in a predominantly Asian population. This new treatment option addresses a significant unmet need for the approximately 11% of the South Korea population living with migraine.

Key Actions

100 South Korea — Ministry of Food and Drug Safety granted marketing authorization Lundbeck

90 Lundbeck announced approval

Entities Involved

priv

Lundbeck

Lundbeck received marketing authorization for its migraine treatment, eptinezumab, in South Korea, expanding its global market presence and potential revenue.

Importance 100 Sentiment 70

cnt

South Korea

South Korea's South Korea — Ministry of Food and Drug Safety granted marketing authorization, providing a new treatment option for its citizens suffering from migraine.

Importance 80 Sentiment 0

govactor

South Korea — Ministry of Food and Drug Safety

The South Korea — Ministry of Food and Drug Safety granted the marketing authorization for eptinezumab in South Korea.

Importance 80 Sentiment 0

per

Johan Luthman

Johan Luthman, EVP and Head of Research and Development at Lundbeck, commented on the significance of the approval for migraine patients in South Korea.

Importance 30 Sentiment 0

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration previously approved eptinezumab for preventive migraine treatment in adults.

Importance 20 Sentiment 0

govactor

International — European Commission

The International — European Commission previously granted marketing authorization for eptinezumab for migraine prophylaxis in adults.

Importance 20 Sentiment 0

alliance

European Union

Eptinezumab received prior approval in the European Union.